1. Home
  2. Directory
  3. New York
  4. Hawthorne
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1487635504

DR. TRACEY A MILLIGAN MD
Prescription History 1487635504
Psychiatry & Neurology - Neurology in Hawthorne, NY

NPI Status: Active since November 07, 2005

Contact Information

19 BRADHURST AVE STE 3850S
HAWTHORNE, NY
ZIP 10532
Phone: (914) 345-1313

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TRACEY A MILLIGAN MD, an active Neurology specialist practicing in Hawthorne, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 182 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 111 claims alone.

Medication Index

L
O
No matching medications currently found on file.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.0
Days Supply 690
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply1,034
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,118.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$162.93

State Avg Cost Per Claim

$291.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 47
30-Day Fills 98.4
Days Supply 2,951
NY State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills63.0
Peer Average Days Supply1,843
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,327.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.25

State Avg Cost Per Claim

$16.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 111
30-Day Fills 225.0
Days Supply 6,727
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills70.3
Peer Average Days Supply1,936
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 117.6% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,951.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.60

State Avg Cost Per Claim

$37.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxtellar Xr

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills21.3
Peer Average Days Supply615
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,912.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$355.72

State Avg Cost Per Claim

$1,080.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TRACEY A MILLIGAN MD provides transparency into local medical care patterns within Hawthorne, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.